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ABSTRACT
Introduction: To compare estimated
glomerular filtration rate measured by serum
creatinine (eGFRcr) and serum cystatin C
(eGFRcys) in patients with type 2 diabetes
mellitus from dapagliflozin clinical trials.
Methods: Post hoc analysis of data pooled from
9 phase 3, randomized, placebo-controlled,
24-week trials of dapagliflozin. The correlation
between eGFRcr and eGFRcys was modeled by a
simple linear regression. The proportions of
patients with eGFR 30 to\60 and C60 mL/
min/1.73 m2 based on creatinine versus
cystatin C were compared.
Results: Of 4745 total patients, 4294 (90.5%)
had serum cystatin C data available for
calculation of eGFRcys. The correlation
between eGFRcr and eGFRcys was poor
(R2 = 30%). Of patients with eGFRcr 30
to\60 mL/min/1.73 m2, 66% had eGFR C60
when recalculated based on cystatin C. Among
patients with eGFRcr C60 mL/min/1.73 m2,
95.8% had eGFR C60 when estimated using
cystatin C. Decreases in HbA1c, body weight,
and systolic blood pressure with dapagliflozin
were similar among patient subgroups defined
by either eGFR estimate and were statistically
significant and clinically meaningful with
dapagliflozin 10 mg/day in most subgroups.
Conclusion: The correlation between eGFRcr
and eGFRcys was poor. Renal function assessed
by eGFRcr may be underestimated, and some
patients may be misdiagnosed with chronic
kidney disease and/or unjustifiably deemed
ineligible for certain antidiabetes medications.
This is in consonance with guidelines
suggesting using eGFRcys as a confirmatory
measure when eGFRcr is between 45 and
\60 mL/min/1.73 m2 with no evidence of
kidney damage and/or in other situations
where eGFRcr may be unreliable.
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INTRODUCTION
Patients with diabetes have an increased risk of
chronic kidney disease (CKD) [1], defined as an
estimated glomerular filtration rate (eGFR) of
\60 mL/min/1.73 m2 or an albumin/creatinine
ratio[30 mg/g for more than 3 months [2]. The
prevalence of CKD among patients with
diabetes in the National Health and Nutrition
Examination Survey (NHANES) from 2007 to
2012 was *40%, and *20% of the diabetes
population had an eGFR\60 mL/min/1.73 m2
[3]. Diabetes is also the major cause of end-stage
renal disease (ESRD) [3]. Because GFR is the best
overall measure of kidney function [2], its
accurate assessment is important for the
diagnosis of CKD and for drug dosing
considerations; many drugs, including some
antidiabetes medications, are eliminated by
the kidney and require dose adjustment in
CKD or depend on kidney function for efficacy
[4].
Glomerular filtration rate can be directly
measured by determining the clearance of
exogenous filtration markers such as
iothalamate, iohexol, or inulin [5]. However,
these methods are time consuming, expensive,
and impractical for routine clinical use.
Therefore, estimates of GFR based on serum
concentrations of the endogenous filtration
marker creatinine are commonly used to assess
kidney function. Serum creatinine
concentrations may be affected by several
factors, including age, sex, ethnicity, muscle
mass, dietary protein intake, and overall health
[6, 7]. Various creatinine-based equations to
assess GFR, most notably the Modification of
Diet in Renal Disease (MDRD) and CKD
Epidemiology Collaboration (CKD-EPI) [2],
have been developed to account for such
factors. These equations may not be suitable in
all patients and may underestimate GFR in
individuals with eGFR 60–80 mL/min/1.73 m2
[8], and notably in patients with eGFR 45 to
\60 mL/min/1.73 m2 [9].
Because of the limitations of
creatinine-based eGFR (eGFRcr), estimates of
GFR based on cystatin C (eGFRcys) have been
proposed as an alternative, less variable measure
of eGFR [10]. Cystatin C is a cysteine protease
inhibitor that is constitutively produced by all
nucleated cells, filtered by the glomerulus, and
reabsorbed by tubular cells, but not secreted by
the renal tubules [11]. Cystatin C is less
influenced than creatinine by the individual
factors noted above, although small effects of
diabetes, inflammation, body mass index,
thyroid status, and steroid therapy on serum
cystatin C concentrations have been described
[2, 12]. Estimates of GFR based on cystatin C
appear to correlate better than ones based on
creatinine with morbidity and mortality in
diverse patient populations, including those
with CKD [9]. In addition, serum cystatin C
concentration may be a better predictor of
progression to ESRD than serum creatinine in
individuals with type 2 diabetes and
albuminuria [13]. Based on these
considerations, the Kidney Disease: Improving
Global Outcomes (KDIGO) guidelines suggest
using eGFRcys as a confirmatory measure when
eGFRcr is between 45 and\60 mL/min/1.73 m2
in patients with no evidence of kidney damage
and/or in other situations in which eGFRcr
may be unreliable [2].
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Accurate estimates of GFR are important not
only for diagnosis and staging of CKD but also
for dose adjustment of drugs that are eliminated
by the kidneys, or for administration of drugs
whose action depends on renal function.
Sodium-glucose cotransporter 2 (SGLT2)
inhibitors, the newest class of antidiabetes
agents, reduce plasma glucose concentrations
by inhibiting the reabsorption of glucose in the
kidney and increasing glucose excretion in the
urine [14]. SGLT2 inhibitor efficacy depends on
the ability of the kidneys to filter glucose and
thus declines with reduced GFR [15–17]. For
example, dapagliflozin should not be used in
patients with eGFR\60 mL/min/1.73 m2 owing
to reduced efficacy and safety considerations
[18].
The objective of this analysis was to compare
assessments of eGFRcr and eGFRcys in patients
with type 2 diabetes pooled from dapagliflozin
phase 3 trials. The results of this analysis may
have important implications for the diagnosis
of CKD and the eligibility of patients for
treatment with antidiabetes drugs that are
limited by renal function.
METHODS
This was a post hoc analysis that included data
pooled from 9 dapagliflozin phase 3,
randomized, double-blind, placebo-controlled,
24-week studies in adult patients (C18 years of
age) with type 2 diabetes mellitus. Dapagliflozin
5 or 10 mg/day or placebo was administered as
monotherapy in treatment-naive patients
(ClinicalTrials.gov identifier, NCT00528372)
[19]; as initial combination therapy with
metformin (NCT00859898) [20]; and as add-on
to the following: metformin (NCT00528879
and NCT00855166) [21, 22], glimepiride
(NCT00680745) [23], sitagliptin ±metformin
(NCT00984867) [24], insulin ± up to 2 other
antidiabetes medications (NCT00673231) [25],
usual care in patients with cardiovascular
disease (NCT01042977) [26], and usual care in
patients with cardiovascular disease and
hypertension (NCT01031680) [27]. Study
designs, inclusion and exclusion criteria, and
primary findings for these 9 studies have been
previously reported in detail [19–27]. This
article is based on previously conducted
studies and does not involve any new studies
of human or animal subjects performed by any
of the authors. The original clinical trials were
designed and monitored in accordance with the
ethical principles of Good Clinical Practice as
defined by the International Conference on
Harmonisation and Declaration of Helsinki.
Institutional review boards or ethics
committees at each study site approved the
protocols, and all patients gave written
informed consent.
Creatinine-based eGFR was calculated using
the MDRD formula: eGFR (mL/min/1.73 m2) =
175 9 (serum creatinine, mg/L)-1.154 9
(age)-0.203 9 (0.742 if female) 9 (1.212 if
African American) [28]. Cystatin C-based eGFR
was calculated as eGFR (mL/min/1.73 m2) =
76.7 9 (serum cystatin, mg/L)-1.19 [10].
The correlation between eGFRcr and
eGFRcys was modeled by a simple linear
regression. The strength of the relationship
between these 2 variables was estimated by the
coefficient of determination, R2, calculated
from the linear regression analysis and
presented as a percentage (R2% = R2 9 100).
Changes from baseline in HbA1c, body
weight, and systolic blood pressure (SBP) at
week 24 (last observation carried forward) in all
patients who received study medication and
had at least 1 post-baseline assessment were
analyzed using an analysis of covariance model
in which treatment, subgroup, and study were
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included in the model as factors. Treatment by
subgroup was included as an interaction term;
and baseline value and study by baseline value
were included as covariates for each GFR
estimation method. P values (without
multiplicity adjustment) for treatment
comparisons were estimated from respective
t tests. All statistical analyses were performed
using SAS procedures (SAS version 9.2, SAS
Institute, Cary, NC, USA).
Safety and tolerability based on adverse events
(AEs), seriousAEs (SAEs),hypoglycemia, laboratory
abnormalities, and vital signs were assessed in all
patients who received study medication.
Hypoglycemia events excluded data after rescue
treatment. Major hypoglycemia was defined as a
symptomatic episode requiring third-party
assistance owing to severe impairment of
consciousness or behavior, with plasma glucose
\3.0 mmol/Landprompt recoverywithglucoseor
glucagon administration. Minor hypoglycemia
was a symptomatic or asymptomatic episode
with plasma glucose \3.5 mmol/L. Other
hypoglycemia was a suggestive episode that was
reported but did not meet the criteria for major or
minor episodes.
RESULTS
A total of 4745 patients were included in this
analysis (Table 1); 4294 (90.5%) had serum
cystatin C data available for calculation of
eGFRcys. Most patients were white and there
were approximately equal numbers of men and
women. In the pooled data set, 12.4% (589/
4745) of patients had baseline eGFRcr 30 to
\60 mL/min/1.73 m2. These patients were
generally older, with a longer duration of
diabetes, and with higher body weight and
body mass index than those with eGFRcr
C60 mL/min/1.73 m2.
In contrast, 7.7% (332/4294) of patients with
available cystatin C data had baseline eGFRcys
30 to \60 mL/min/1.73 m2 (Table 2). Of
patients with moderate renal impairment
(CKD stage 3, eGFR 30 to \60 mL/min/
1.73 m2) [2] based on creatinine, 66% had
eGFR C60 mL/min/1.73 m2 when recalculated
based on cystatin C. Among patients with
eGFRcr C60 mL/min/1.73 m2, 95.8% had
eGFRcys C60 mL/min/1.73 m2. Results were
similar in women and men. The overall
correlation between eGFRcr and eGFRcys was
poor, R2 = 30% (Fig. 1).
Adjusted mean changes from baseline in
HbA1c, body weight, and SBP with
dapagliflozin were generally similar within
patient subgroups stratified by either
creatinine- or cystatin C-based estimates of
GFR (Fig. 2). Statistically significant and
clinically meaningful changes with
dapagliflozin 10 mg/day versus placebo were
observed in most subgroups. Changes from
baseline in HbA1c appeared to be larger in
patients with eGFR C60 mL/min/1.73 m2 than
in those with eGFR 30 to\60 mL/min/1.73 m2,
regardless of GFR estimation method.
Within the eGFR ranges estimated by either
creatinine or cystatin C, the proportion of
patients with C1 AE was similar between
placebo and dapagliflozin-treated patients
(Table 3). A greater proportion of patients with
eGFR 30 to\60mL/min/1.73 m2 experienced
AEs than those with eGFR C60mL/min/
1.73 m2. Similar findings were observed for the
proportion of patients with C1 SAE and with C1
AE leading to discontinuation. Genital infections
were more frequent with dapagliflozin compared
with placebo regardless of eGFR group or
estimation method, whereas urinary tract
infections were more common in patients with
eGFR 30 to\60 mL/min/1.73 m2 than in those
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with eGFR C60 mL/min/1.73 m2 in both the
dapagliflozin and placebo groups. A greater
proportion of patients with eGFR 30 to
\60 mL/min/1.73 m2 compared with those
with eGFR C60 mL/min/1.73 m2 had renal AEs
that included renal impairment, renal failure,
GFR decrease, or blood creatinine or cystatin C
increase. Within the 30 to\60mL/min/1.73 m2
group, renal AEs were more frequent with
dapagliflozin than with placebo. AEs of
hypovolemia (hypotension, dehydration, or
hypovolemia) were uncommon and similar
across all treatment and eGFR groups. The
incidence of hypoglycemia was variable across
groups but appeared to be higher in patients
with eGFR 30 to\60 mL/min/1.73 m2; events of
major hypoglycemia were rare (B0.1%) across
eGFR and treatment groups.
DISCUSSION
Accurate assessment of GFR is essential for the
diagnosis of CKD [2] and for use in dose
adjustment of several antidiabetes drugs [4]. In
this analysis, 66% of patients with type 2
diabetes classified as having moderate renal
impairment at baseline (CKD stage 3) when
GFR was estimated based on serum creatinine
had mild or no renal impairment when GFR was
estimated based on serum cystatin C. Such
patients would be erroneously classified with
CKD, with associated treatment and healthcare
implications, and would be ineligible to receive
antidiabetes medications that are GFR-limited,
such as SGLT2 inhibitors and metformin [29], or,
alternatively, would be prescribed lower, possibly
less effective doses of certain antidiabetes
medications that require dose adjustments
based on GFR, such as some sulfonylureas,
dipeptidyl peptidase-4 inhibitors, and
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Equations to estimate GFR based on serum
creatinine, including MDRD and CKD-EPI, may
not be accurate in all patients and may
underestimate GFR, particularly in patients
with eGFR 45 to \60 mL/min/1.73 m2 [9]. A
number of analyses have suggested that eGFR
based on serum cystatin C may be a more
accurate measure of GFR than creatinine-based
estimates in diverse patient populations
[30–32], including those with diabetes [13,
33–35]. In addition, eGFRcys compared with
eGFRcr may better predict health outcomes,
including: all-cause and cardiovascular
mortality in individuals with diabetes [36],
cardiovascular events in patients with diabetes
and CKD (defined as eGFR \60 mL/min/
1.73 m2) [37], and overall mortality in older
individuals (mean age 78 years) with diabetes
[38]. Because cystatin C is less influenced than
creatinine by factors other than GFR and
because eGFRcys appears to better estimate
GFR in the range of 45 to \60 mL/min/
1.73 m2, clinical practice guidelines suggest
that eGFRcys be used as confirmation of
eGFRcr or in combination with eGFRcr to
better estimate GFR in such individuals [2, 9,
39].
In our pooled analysis of data from adult
patients with type 2 diabetes who participated
in dapagliflozin clinical trials, approximately
two-thirds of patients with eGFRcr 30 to
\60 mL/min/1.73 m2 had eGFR C60 mL/min/
1.73 m2 when measured by cystatin C. This
finding is consistent with observations in other
studies. For example, in a meta-analysis of 16
studies in which measurements of eGFRcr and
eGFRcys were available in populations with a
broad range of kidney function (N = 93,710),
42% of individuals with eGFRcr 45 to\60 mL/
min/1.73 m2 had eGFR C60 mL/min/1.73 m2
when measured by cystatin C [9]. Also,
eGFRcys, alone or in combination with
eGFRcr, showed a better correlation between
eGFR category and risk of death and ESRD than
Fig. 1 Correlation of baseline eGFRcr vs eGFRcys. DAPA dapagliﬂozin, eGFR estimated glomerular ﬁltration rate, eGFRcr
creatinine-based eGFR, eGFRcys cystatin C-based eGFR, PBO placebo, R2 coefﬁcient of determination
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eGFRcr. In another analysis of participants
(N = 11,909) in the Multi-Ethnic Study of
Atherosclerosis and the Cardiovascular Health
Study, only 21–56% of individuals (depending
on age) with eGFRcr\60 mL/min/1.73 m2 had
GFR \60 mL/min/1.73 m2 when measured by
cystatin C [32], and eGFRcys was a better
predictor of death, cardiovascular disease,
heart failure, and ESRD than was eGFRcr in
individuals with CKD.
Some studies, however, have reported less
discordant results between eGFRcr and eGFRcys.
For example, in 3 cohorts of patients with type
1 or 2 diabetes (N = 1165), 65–77% of patients
with eGFRcr 30 to\60 mL/min/1.73 m2 had the
same range of eGFR when measured with
cystatin C; 4–14% of patients with eGFRcr 30
to\60 mL/min/1.73 m2 had eGFRcys
60–89 mL/min/1.73 m2 [35].
In our analysis, changes from baseline in
HbA1c with dapagliflozin compared with
placebo appeared greater in patients with
eGFR C60 mL/min/1.73 m2 than in those with
eGFR 30 to\60 mL/min/1.73 m2, regardless of
calculation method. This is consistent with the
mechanism of action of SGLT2 inhibitors [14]
and with published studies of dapagliflozin [15]
and other SGLT2 inhibitors, in which the
efficacy decreased with lower GFR [16, 17].
Changes in body weight and SBP were
generally similar across the 2 eGFR ranges. The
proportion of patients with AEs, including renal
AEs, SAEs, and hypoglycemia, was greater in
patients with eGFR 30 to\60 mL/min/1.73 m2
compared with those with eGFR C60 mL/min/
1.73 m2, perhaps reflecting the overall health
status of these individuals. Occurrence of these
AEs in patients with eGFR 30 to\60 mL/min/
bFig. 2 Adjusted mean change from baseline in HbA1c (a),
body weight (b), and seated SBP (c) stratiﬁed by
creatinine-based and cystatin C-based eGFR. CI conﬁ-
dence interval, DAPA dapagliﬂozin, eGFR estimated
glomerular ﬁltration rate, eGFRcr creatinine-based eGFR,
eGFRcys cystatin C-based eGFR, PBO placebo, SBP
systolic blood pressure. *P\0.0001, P = 0.015, Data
not shown, n = 8–9, §P = 0.021, }P = 0.013, #P =
0.0002 versus placebo
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1.73 m2 was similar between dapagliflozin and
placebo, except for renal AEs, which were more
frequent with dapagliflozin. Similar to other
studies with dapagliflozin [40], genital
infections were more frequent with
dapagliflozin compared with placebo and
occurred in similar proportions of patients
across eGFR ranges.
In spite of the poor correlation between
eGFRcr and eGFRcys and the finding that
approximately two-thirds of patients diagnosed
with CKD stage 3 by the former had only mild
renal impairment based on the latter. The
efficacy and safety profiles of dapagliflozin in
this pooled analysis seemed unaffected by the
GFR estimation method, suggesting that whereas
many patients could have potentially benefited
from being eligible to receive dapagliflozin based
on eGFRcys, the risk profile in these patients
would have remained unchanged.
Strengths of this analysis include a large
study population with a range of type 2 diabetes
disease duration and the use of data from
prospective, randomized, placebo-controlled
trials. An important limitation of this analysis
was that the population of patients was
relatively homogeneous, predominantly white,
and 56–65 years of age. An additional limitation
was the small proportion of patients with eGFR
30 to \60 mL/min/1.73 m2. Whether these
findings can be generalized to other races and
age groups is unknown, but because serum
cystatin C concentrations appear to be less
affected by age and race than serum creatinine
[12], eGFRcys may be a more accurate estimate
of GFR in some patients.
CONCLUSION
The results of this analysis suggest that the
correlation between eGFRcys and eGFRcr in
patients with type 2 diabetes may be even
poorer than previously reported in a broader
population. Renal function as assessed by
eGFRcr may be underestimated, and many
patients may be misdiagnosed with CKD and/
or unjustifiably deemed ineligible to receive
certain antidiabetes medications. These
findings, together with existing data on
correlation between eGFRcys and
cardiovascular and renal outcomes, support
recommendations that eGFRcys, alone or in
combination with eGFRcr, be used when
eGFRcr is in the range of 45 to\60 mL/min/
1.73 m2 and/or in other situations in which
eGFRcr may be unreliable. The use of eGFRcys
may provide a better estimate of GFR in patients
with type 2 diabetes.
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